CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SEATTLE, September 21, 2022 /PRNewswire/ — CTI BioPharma Corp. (NASDAQ: CTIC) today announced the granting of stock awards to two new employees as stock incentive awards outside of the Company’s Amended and Restated 2017 Equity Incentive Plan (but subject to the terms of the Amended and Restated 2017 Equity Incentive Plan) and material to acceptance the employees at the company. The Equity Awards were approved on September 20, 2022 and September 21, 2022each in accordance with Nasdaq Listing Rule 5635(c)(4).

(PRNews photo/CTI BioPharma Corp.)

(PRNews photo/CTI BioPharma Corp.)

The employees received options to purchase a total of 140,000 common shares of CTI BioPharma. The options are granted on the individual employee’s grant date (the “Grant Date”) and all stock options included in stock incentive awards have an exercise price equal to the closing price of CTI BioPharma common stock on the relevant grant date. One quarter of the options will vest on each anniversary of the employee’s grant date, subject to the employee’s continued employment with CTI BioPharma on such vesting dates. The options have a term of ten years.

Also Read :  NRC Health Announces Sponsorship of Creative Learning Event

About CTI BioPharma Corp.
We are a commercial biopharmaceutical company focused on acquiring, developing and commercializing novel targeted therapies for blood-related cancers that offer unique benefits for patients and their healthcare providers. CTI has one FDA approved product, VONJO® (pacritinib), a JAK2 and IRAK1 inhibitor sparing JAK1. VONJO is approved for the treatment of adults with intermediate- or high-risk primary or secondary myelofibrosis (post-polycythemia vera or postessential thrombocythemia) and a platelet count below 50 × 109/L This indication is approved under FDA accelerated approval based on splenic volume reduction. Continued approval for this indication may be subject to verification and characterization of clinical benefit in one or more confirmatory studies. CTI is conducting the Phase 3 PACIFICA study of VONJO in patients with myelofibrosis and severe thrombocytopenia as a post-marketing requirement.

Also Read :  This Financial Tool is the Most Stressful Form of Consumer Debt

BYJO® is a registered trademark of CTI BioPharma Corp.

CTI BioPharma investor contacts:
Argot partner
[email protected]



To download multimedia, view the original content: https://www.prnewswire.com/news-releases/cti-biopharma-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-301630407.html

SOURCE CTI BioPharma Corp.

Also Read :  ASE announces Dr. William Chen is the 2022 recipient of IMAPS Daniel C. Hughes, Jr. Memorial Award

Source link